Montelukast Viatris

Montelukast, the active ingredient in Montelukast Viatris, is a Leukotriene receptor antagonist presented as a unknown/unknown for Oral use. It treats asthma, allergic rhinitis and exercise‑induced bronchoconstriction in appropriate patients.

GNH USA supplies Montelukast Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control airway inflammation and allergic symptoms. - Asthma: improves long‑term control and reduces the frequency of exacerbations. - Allergic rhinitis: relieves nasal congestion, sneezing and itchy eyes. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate discomfort. - Abdominal pain: intermittent stomach discomfort. - Cough: occasional dry cough. - Sore throat: mild irritation of the throat. - Nasopharyngitis: common cold‑like symptoms. - Diarrhoea: loose stools.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips or tongue. - Allergic reactions: rash, itching or hives. - Mood changes: agitation, depression or anxiety. - Suicidal thoughts: rare but reported ideation. - Hepatic dysfunction: elevated liver enzymes. - Severe bronchospasm: paradoxical worsening of breathing.

Use Montelukast with clinical oversight and consider patient‑specific factors. - Hypersensitivity: avoid if known allergy to montelukast or excipients. - Psychiatric disorders: monitor for mood changes or suicidal ideation. - Pregnancy: use only if potential benefit justifies potential risk, as data are limited. - Pediatric use: follow age‑specific labeling and dosing recommendations. - Drug interactions: review concomitant medications for enzyme inducers or inhibitors. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Montelukast may interact with drugs that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid): - Phenobarbital: induces hepatic enzymes, reducing montelukast exposure. - Rifampin: strong enzyme inducer that lowers plasma concentrations. - St. John's wort: herbal inducer that may diminish therapeutic effect.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of anticoagulant effect. - Beta‑blockers: may blunt bronchodilatory response. - Other leukotriene modifiers: increased risk of adverse events. - Fluconazole: enzyme inhibitor that could raise montelukast levels. - Cyclosporine: possible pharmacokinetic interaction requiring observation.